Research Article
Serum Interleukin 17 Levels in Patients with Crohn’s Disease: Real Life Data
Table 2
Disease features and medications of Crohn’s disease patients and assessment according to IL17 measurements.
| | (%) | IL17 (ng/L) | |
| Activity | | | >0.05 | Active | 20 | | | Inactive | 30 | | | Behavior (%) | | | >0.05 | Nonstricturing and nonpenetrating | 29 | | | Penetrating | 18 | | | Stricturing | 3 | | | Location | | | >0.05 | Ileal | 21 | | | Ileocolonic | 27 | | | Colonic | 2 | | | Treatment groups | | | >0.05 | Mesalazine group | 16 | | | Immunomodulatory group | 22 | | | Anti-TNF group | 12 | | | Immunomodulatory + anti-TNF | 34 | | |
|
|